Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Arch Ital Urol Androl ; 94(2): 160-165, 2022 Jun 29.
Artículo en Inglés | MEDLINE | ID: mdl-35775339

RESUMEN

OBJECTIVES: To compare the cost-effectiveness of a short biparametric MRI (BP-MRI) with that of contrast-enhanced multiparametric MRI (MP-MRI) for the detection of prostate cancer in men with elevated prostatespecific antigen (PSA) levels. MATERIALS AND METHODS: We compared two diagnostic procedures for detection of prostate cancer (Pca), BP-MRI and MP-MRI, in terms of quality-adjusted life years (QALY), incremental costeffectiveness ratio (ICER) and net monetary benefit (NMB) for a hypothetical cohort of 10,000 patients. We compared two scenarios in which different protocols would be used for the early diagnosis of prostate cancer in relation to PSA values. Scenario 1. BP-MRI/MP-MRI yearly if > 3.0 ng/ml, every 2 years otherwise; Scenario 2. BP-MRI/MP-MRI yearly with age-dependent threshold 3.5 ng/ml (50-59 years), 4.5 ng/ml (60-69 years), 6.5 ng/ml (70-79 years). RESULTS: BP-MRI was more effective than the comparator in terms of cost (160.10 € vs 249.99€) QALYs (a mean of 9.12 vs 8.46), ICER (a mean of 232.45) and NMB (a mean of 273.439 vs 251.863). BP-MRI was dominant, being more effective and less expensive, with a lower social cost. Scenario 2 was more cost-effective compared to scenario 1. CONCLUSIONS: Our results confirmed the hypothesis that a short bi-parametric MRI protocol represents a cost-efficient procedure, optimizing resources in a policy perspective.


Asunto(s)
Imágenes de Resonancia Magnética Multiparamétrica , Neoplasias de la Próstata , Análisis Costo-Beneficio , Humanos , Imagen por Resonancia Magnética/métodos , Masculino , Persona de Mediana Edad , Antígeno Prostático Específico , Neoplasias de la Próstata/diagnóstico por imagen , Neoplasias de la Próstata/patología
2.
Eur Urol Focus ; 8(1): 276-282, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33419709

RESUMEN

BACKGROUND: The gold standard treatment for solitary medium-sized (1-2 cm) renal stones is not defined by recent guidelines, since management modalities including shockwave lithotripsy (SWL), retrograde intrarenal surgery (RIRS), and percutaneous nephrolithotomy (PNL) are recommended. Improved ability to predict patient outcomes would aid in patients' counseling and decision-making. OBJECTIVE: To develop a nomogram predicting treatment failure, based on preoperative clinical variables, to be used in the preplanning setting. DESIGN, SETTING, AND PARTICIPANTS: We recruited 2605 patients from 14 centers and carried out a multicenter retrospective analysis of 699 SWL, 1290 RIRS, and 616 PN L procedures performed as first-line treatment for 1-2-cm kidney stones. The variables evaluated included age, gender, previous renal surgery, body mass index, stone size, location, stone density, skin-to-stone distance, presence of urinary tract infections (UTIs), and hydronephrosis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariate logistic regression was fitted to predict treatment failure, defined as the presence of residual fragments >4 mm. A nomogram was developed based on the coefficients of the logit function. RESULTS AND LIMITATIONS: A total of 2431 (93.3%) patients were stone free; 174 (6.7%) treatment failures were recorded and considered the event to be predicted. On univariate analysis, type of procedure, preoperative hydronephrosis, stone density, stone location, and laterality turned out to be statistically significant. Skin-to-stone distance, UTIs, and previous renal surgery were predictors of failure on multivariate analysis. Each variable was given a score based on statistical relevance. The main limitation of the current study is its retrospective nature. CONCLUSIONS: This nomogram provides a prediction of treatment failure and need of reintervention for medium-sized kidney stones. External validation is needed to determine its reproducibility and validity. PATIENT SUMMARY: We developed a preoperative model of treatment outcomes for 1-2-cm kidney stones. Its application may assist urologists to counsel patients with regard to stone management modality.


Asunto(s)
Hidronefrosis , Cálculos Renales , Humanos , Cálculos Renales/cirugía , Nomogramas , Reproducibilidad de los Resultados , Estudios Retrospectivos
3.
Arch Ital Urol Androl ; 93(4): 445-449, 2021 Dec 21.
Artículo en Inglés | MEDLINE | ID: mdl-34933542

RESUMEN

PURPOSE: To assess the prevalence of nocturnal polyuria (NP) in males performing uroflowmetry (UF) for lower urinary tract symptoms (LUTS), the impact of NP on UF outcomes, and bladder emptying, the association between NP and LUTS. MATERIALS AND METHODS: Men scheduled for UF were recruited in two Centres. Data collected were medical history, IPSS, UF, post-void residual urine volume (PVR), 3-day frequency-volume charts (FVC). The NP index was used to assess NP with a threshold of ≥ 33%. The relationship between NP and patient's aging was assessed. RESULTS: 162 patients were included in the analysis. Mean age was 70.95 ± 8.04 years. The prevalence of NP was 54.9% (89/162). 110 (68%) patients reported nocturia, and among these, NP was documented in 76 (69%). Nocturia was found in 85% (76/89) of the population with NP. Total IPSS score, IPSS items #1, #2 and #7 showed a significant difference in men with NP compared with those without. Maximum flow rate and PVR did not significantly change comparing men with or without NP. Mean voiding volume (VV) of the night-time micturitions was significantly higher in men with NP compared to those without NP (532.1 ± 275.6 ml vs 175 ± 168.7 ml respectively, p < 0001), while mean VV day-time micturitions and mean VV at UF did not change between groups. CONCLUSIONS: NP had a high prevalence in men with LUTS performing UF. Aged males were more commonly affected by NP. Data demonstrated a strong relationship between NP and nocturia and increased urinary frequency while voiding symptoms were poorly related to NP.


Asunto(s)
Síntomas del Sistema Urinario Inferior , Nocturia , Hiperplasia Prostática , Anciano , Humanos , Síntomas del Sistema Urinario Inferior/epidemiología , Masculino , Persona de Mediana Edad , Nocturia/epidemiología , Poliuria/epidemiología , Micción
4.
Arch Ital Urol Androl ; 89(4): 325-326, 2017 Dec 31.
Artículo en Inglés | MEDLINE | ID: mdl-29473390

RESUMEN

Pneumatic nail guns are hand-held tools commonly utilized in both industrial and non occupational setting. These devices facilitate production and boost efficiency but also can be a potential cause of serious injuries. Nail guns are the most frequent tool associated trauma with hospitalization among construction workers. The most common sites of injuries are the hand or fingers followed by the lower extremities. We report the first case in literature of a work nail gun injury to male external genitalia.


Asunto(s)
Accidentes de Trabajo , Escroto/lesiones , Heridas Penetrantes/etiología , Materiales de Construcción , Humanos , Masculino , Persona de Mediana Edad , Escroto/patología , Heridas Penetrantes/patología
5.
Int J Surg Pathol ; 24(5): 443-7, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26873338

RESUMEN

Well-differentiated papillary mesothelioma (WDPM) affecting the tunica vaginalis testis is a rare tumor, and very little is known about the clinicopathological spectrum of this variant as a distinct entity. Most patients with WDPM suffer from scrotal pain or swelling, but hydrocele seems to be the most common presenting symptom. These lesions are usually not aggressive and are accompanied by an indolent clinical behavior. In this article, we report the first case known of WDPM in an undescended testis, and in addition, we review the literature for similar cases.


Asunto(s)
Criptorquidismo/patología , Mesotelioma/patología , Neoplasias Testiculares/patología , Adulto , Biomarcadores de Tumor/análisis , Humanos , Inmunohistoquímica , Masculino , Mesotelioma/diagnóstico , Neoplasias Testiculares/diagnóstico
6.
Urol Int ; 95(1): 44-9, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25720418

RESUMEN

BACKGROUND: Pelvic organ prolapse is a common condition, affecting about 50% of women with children. The aim of our study was to evaluate results and complication rates in a consecutive series of female patients undergoing robot-assisted laparoscopic hysterosacropexy (RALHSP). MATERIALS AND METHODS: We performed a medical record review of female patients with uterine prolapse who had consecutively undergone RALHSP from February 2010 to 2013 at our department. RESULTS: Fifteen patients were included in the analysis. All patients had uterine prolapse stage ≥ II and urodynamic stress urinary incontinence. The mean age was 58.26 years. According to the Clavien-Dindo system, 4 out of 15 patients (26.6%) had grade 1 early complications and 1 patient had a grade 2 complication. At a median follow-up of 36 months, there was a significant prolapse relapse rate of 20% (3/15). CONCLUSION: In our hands RALHSP is easy to perform, with satisfying mid-term outcomes and a low complication rate.


Asunto(s)
Procedimientos Quirúrgicos Ginecológicos/métodos , Laparoscopía/métodos , Prolapso de Órgano Pélvico/cirugía , Procedimientos Quirúrgicos Robotizados/métodos , Incontinencia Urinaria de Esfuerzo/cirugía , Procedimientos Quirúrgicos Urológicos/métodos , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Periodo Intraoperatorio , Persona de Mediana Edad , Complicaciones Posoperatorias , Periodo Posoperatorio , Estudios Retrospectivos , Mallas Quirúrgicas , Resultado del Tratamiento , Urodinámica , Adulto Joven
7.
Urol Int ; 94(3): 270-85, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25170543

RESUMEN

BACKGROUND: Benign prostatic hyperplasia and prostate cancer (PCA) alter the normal growth patterns of zonal anatomy with changes of prostate volume (PV). Chronic inflammatory infiltrates (CII) type IV are the most common non-cancer diagnosis of the prostate after biopsy. OBJECTIVE: To evaluate associations of both PV index (PVI), i.e. the ratio of transitional zone volume (TZV) to peripheral zone volume (PZV), and CII with PCA in patients undergoing biopsy. SUBJECTS AND METHODS: Between January 2007 and December 2008, 268 consecutive patients who underwent prostate biopsy were retrospectively evaluated. PV and TZV were measured by transrectal ultrasound. PZV was computed by subtracting the PV from the TZV. CII were evaluated according to standard criteria. Significant associations of PVI and the presence of CII (CII+) with PCA risk were assessed by statistical methods. RESULTS AND LIMITATIONS: We evaluated 251 patients after excluding cases with painful rectal examinations, prostate-specific antigen (PSA) >20 µg/ml and metastases. The PCA detection rate was 41.1%. PVI was a negative independent predictor of PCA. A PVI ≤1.0 was directly [odds ratio (OR) = 2.36] associated with PCA, which was detected more frequently in patients with a PVI ≤1.0 (29.1%) than in those with a PVI >1.0 (11.9%). CII+ was inversely (OR = 0.57) and independently associated with PCA, which was detected less frequently in cases with CII (9.9%) than in those without CII (21.1%). Potential study limitations might relate to the fact that PV was not measured by prostatectomy specimens and there was PSA confounding for CII and PCA. CONCLUSIONS: Low values of PVI are directly associated with risk of PCA, which was almost 2.5 times higher in patients with a PVI ≤1.0. The PVI might be an effective parameter for clustering patients at risk of PCA. CII+ was inversely associated with risk of PCA and decreased the probability of detecting PCA by 43%. The role of the PVI and CII in PCA carcinogenesis needs further research.


Asunto(s)
Inflamación/diagnóstico , Próstata/patología , Neoplasias de la Próstata/diagnóstico , Anciano , Biopsia , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Probabilidad , Antígeno Prostático Específico/sangre , Prostatectomía , Hiperplasia Prostática/patología , Neoplasias de la Próstata/patología , Estudios Retrospectivos , Factores de Riesgo
8.
Urol Int ; 95(1): 120-4, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25138359

RESUMEN

In the non-industrialized countries of Africa and Asia obstetric fistulas are more frequently caused by prolonged labour, whereas in countries with developed healthcare systems they are generally the result of complications of gynaecological surgery or, rarely, benign pathologies like inflammation or foreign bodies. A 22-year-old woman was brought to the gynaecology clinic because of foul-smelling vaginal discharge. On pelvic examination a ring-like foreign body was impacted between the anterior and posterior vaginal wall. MRI scan confirmed the presence of a cylindrical foreign body in the vagina and the patient revealed that she had 'involuntarily' inserted a plastic bubble bath cap into the vagina. At surgery removal of the cap was difficult and at the end of the manoeuver evidence of a huge urethro-vesico-vaginal fistula occurred. The patient was discharged with bilateral ureteral stents and suprapubic catheter. After 3 months we performed an end-to-end anastomotic urethroplasty to repair the urethral avulsion and restored the bladder/trigonal and vaginal/cervical defects with 3 layers of sutures; 3 months later the patient had no complaints. Complex genital fistulas represent an extremely debilitating morbidity. In our case, a vaginal approach was successful, but the choice between an abdominal or vaginal approach depends on the surgeon's experience and training.


Asunto(s)
Cuerpos Extraños/complicaciones , Enfermedades Ureterales/etiología , Uretra/cirugía , Vagina/cirugía , Fístula Vesicovaginal/etiología , Fístula Vesicovaginal/cirugía , Anastomosis Quirúrgica , Femenino , Procedimientos Quirúrgicos Ginecológicos , Humanos , Imagen por Resonancia Magnética , Enfermedades Ureterales/cirugía , Vejiga Urinaria/cirugía , Incontinencia Urinaria/etiología , Incontinencia Urinaria/cirugía , Adulto Joven
9.
Arch Ital Urol Androl ; 86(3): 208-11, 2014 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-25308586

RESUMEN

BACKGROUND: Chronic inflammatory infiltrate (CII) might be involved in prostate cancer (PCA) and benign hyperplasia (BPH); however, its significance is controversial. Chronic inflammatory prostatitis type IV is the most common non cancer diagnosis in men undergoing biopsy because of suspected PCA. OBJECTIVE: To evaluate potential associations of coexistent CII and PCA in biopsy specimens after prostate assessment. DESIGN, SETTING, AND PARTICIPANTS: Between January 2007 and December 2008, 415 consecutive patients who underwent prostate biopsy were retrospectively evaluated. The investigated variables included Age (years) and PSA (ug/l); moreover, CII+, glandular atrophy (GA+), glandular hyperplasia (GH+), prostate Intraepithelial neoplasm (PIN+), atypical small acinar cell proliferation (ASAP+) and PCA positive cores (P+) were evaluated as categorical and continuous (proportion of positive cores). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations of CII+ and PCA risk were assessed by statistical methods. RESULTS AND LIMITATIONS: In the patient population, a biopsy core positive for PCA was detected in 34.2% of cases and the rate of high grade PCA (HGPCA: bGS ! 8) resulted 4.82%. CII+ significantly and inversely associated with a positive biopsy core P+ (P < 0.0001; OR = 0.26) and HGPCA (P = 0.0005; OR = 0.05). Moreover, the associations indicated that patients with coexistent CII+ on needle biopsy were 74% less likely to have coexistent PCA than men without CII+ as well as 95% less likely to have HGPCA in the biopsy core than men without coexistent CII+. There were limits in our study which was single centre and included only one dedicated pathologist. CONCLUSIONS: There was an inverse association of chronic inflammation of the prostate type IV and risk of PCA; moreover, HGPCA was less likely to be detected in cancers associated with coexistent CII. In prostate microenvironment, prostate chronic inflammation may be protective; however, its role in PCA carcinogenesis remains controversial and needs further research.

10.
Arch Ital Urol Androl ; 86(3): 205-7, 2014 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-25308585

RESUMEN

Stress urinary incontinence (SUI) affects a large proportion of middle-aged and elderly women. When all conservative means are ineffective, a surgical treatment including retropubic suspension, pubovaginal and tension-free slings, is contemplated. Intra-urethral injections with bulking agents have been used as an alternative to the mentioned surgical procedures with alternate results. Many urethral bulking agents are available, such as bovine glutaraldehyde cross linked (GAX) collagen, polytetrafluoroethylene (Teflon), polydimethyl-sillxane elastomer (silicone), carbon coated zirconium beads, hyaluronic acid/dextranomer, and autologous tissues such as fat and cartilage. These substances may be injected in a retrograde or antegrade fashion in the periurethral tissue and whether one route of injection is better than another is not well documented in the literature. We briefly describe the main injection techniques and devices of the most common bulking agents used in the treatment of female SUI.

11.
Urol Int ; 92(1): 35-40, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24051504

RESUMEN

OBJECTIVES: To reduce short-term complications of radical cystectomy (RC) and intestinal urinary diversion with vescica ileale Padovana (VIP) neobladder, we described and assessed an enhanced recovery protocol (ERP) in a series of consecutive patients. METHODS: An ERP was introduced focusing on reduced bowel preparation, standardized feeding and analgesic regimens. We analyzed the outcomes with all patients consecutively undergoing RC and VIP neobladder who met the following inclusion criteria: American Society of Anesthesiologists score <3; absence of malnutrition according to the Mini Nutritional Assessment-Short Form criteria; absence of inflammatory bowel diseases. RESULTS: Thirty-one consecutive patients were recruited to undergo our ERP. Mean age of patients was 62.16 years. No patients died due to surgical complications. Nine of 31 patients experienced complications (29.03%), none requiring surgical intervention. According to Clavien grading, all complications were grade <2. CONCLUSION: The application of our ERP to our patients undergoing RC and VIP neobladder contributed to reduce postoperative morbidity.


Asunto(s)
Cistectomía/efectos adversos , Complicaciones Posoperatorias/prevención & control , Estructuras Creadas Quirúrgicamente , Neoplasias de la Vejiga Urinaria/cirugía , Vejiga Urinaria/cirugía , Derivación Urinaria/efectos adversos , Anciano , Analgésicos/administración & dosificación , Ingestión de Alimentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estado Nutricional , Cuidados Preoperatorios , Recuperación de la Función , Factores de Tiempo , Resultado del Tratamiento , Vejiga Urinaria/patología , Vejiga Urinaria/fisiopatología , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/fisiopatología
12.
Urologia ; 79(2): 90-6, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22610844

RESUMEN

INTRODUCTION AND AIM OF THE STUDY: Sacral neuromodulation has been used as a safe, effective treatment option for patients with lower urinary tract dysfunction (LUTD). Several clinical studies demonstrated its positive effects on refractory urge incontinence, non-osbstructive urinary retention, urgency frequency syndrome, as well as on other non- urological disorders, such as fecal incontinence and chronic constipation. The aim of this research project was to evaluate the efficacy and safety of sacral neuromodulation on the management of LUTD refractory to the standardized first line treatment options. MATERIALS AND METHODS: We retrospectively collected and evaluated data from patients undergoing sacral neuromodulations between September 2001 and November 2010 in 4 Urological Centres of North-East Italy. The patients were affected by Overactive Bladder Syndrome (OAB), Urinary Retention (UR), Fecal Incontinence (FI), Constipation (CO), Chronic Pelvic Pain (CPP). All the patients were evaluated with voiding diaries, before and after implantation.Patients included in the present evaluation were followed up in a network of 4 Italian urological centres, which participate to in the Italian Clinical Service project - a national urological database and medical care project aiming at describing and improving the use of implantable urological devices in the Italian clinical practice. Continuous normally distributed variables were reported as the mean value ± standard deviation (SD). Continuous non-normally distributed variables were presented as the median values and an interquartile range (IQR). The t-test and Wilcoxon test were used to compare continuous variables, as appropriate. A two-sided p <0.05 was considered statistically significant. RESULTS: Overall, 157 patients underwent implantation of sacral neuromodulator during the period under review. Eighty-three out of 157 (53%) patients complained of OAB; 52 (33%) of UR; 5 (3%) of faecal incontinence; 4 (2%) of chronic constipation; 12 (8%) of CPP. The median follow- up was 11 months (IQR 1 - 91 months). In patients treated for OAB, we documented a statistically significant reduction in the mean number of: incontinence episodes/die, pads/die, daily micturitions, nocturnal micturitions and global micturitions. In patients treated for UR, we observed a statistically significant reduction in the mean post- voiding residual volume and in the number of self catheterization. Interpretation of results: It is difficult to translate into quantifiable data the subjective perception of improvement of the symptoms expressed by the patients, as they are frequently subjective perceptions, not always numeric data. This subjective perception makes it difficult to the clinician to evaluate the real outcomes of this procedure, and makes it difficult to achieve a complete follow-up. CONCLUSIONS: This multicenter research project confirmed the midterm safety and effectiveness of sacral neuromodulation in the treatment of refractory overactive bladder syndrome and urinary retention, showing high cure rates and low complication rates.


Asunto(s)
Terapia por Estimulación Eléctrica , Trastornos Urinarios/terapia , Estreñimiento/fisiopatología , Estreñimiento/terapia , Terapia por Estimulación Eléctrica/efectos adversos , Terapia por Estimulación Eléctrica/métodos , Electrodos Implantados , Incontinencia Fecal/fisiopatología , Incontinencia Fecal/terapia , Humanos , Italia , Plexo Lumbosacro/fisiopatología , Dolor Pélvico/patología , Dolor Pélvico/terapia , Complicaciones Posoperatorias/fisiopatología , Complicaciones Posoperatorias/terapia , Estudios Retrospectivos , Región Sacrococcígea , Resultado del Tratamiento , Vejiga Urinaria Neurogénica/fisiopatología , Vejiga Urinaria Neurogénica/terapia , Vejiga Urinaria Hiperactiva/patología , Vejiga Urinaria Hiperactiva/terapia , Retención Urinaria/patología , Retención Urinaria/terapia , Trastornos Urinarios/fisiopatología
13.
Neurourol Urodyn ; 25(4): 301-6; discussion 307, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16688711

RESUMEN

AIMS: A review of the international literature on urogynecology was performed to focus on the actual role of perineal ultrasound. It is an increasingly used tool for the assessment of pelvic floor dysfunction and incontinence. In recent years ultrasound studies have predominated but there is little information on normal values and confusion on methodology and measurements. The aim of this study is to report the data available in the Literature about ultrasound as investigational evaluation helpful in diagnosing of urinary incontinence and urethral hypermobility, to document pelvic floor anatomy and to assess anatomic and functional changes after surgery. METHODS: A MEDLINE search was conducted using combinations of heading terms: perineal, ultrasound, pelvic floor, urinary incontinence, pelvic organ prolapse. RESULTS: Ultrasound has become an indispensable diagnostic procedure in urogynecology. Perineal, introital, and endoanal ultrasound are the most recommended techniques and the results comprise qualitative and quantitative findings. These are important for determining the localization of the bladder neck and vesico-urethral junction and also for pre- and postoperative comparisons, and moreover for clinical applications and scientific investigations. CONCLUSIONS: There are as yet little data and there is a need to find in the near future more standard and objective parameters for the diagnosis of urinary incontinence. They will be obtained by means of more accurate analysis and comparison of the parameters, leading to a more clinically useful diagnostic test and assuring reliable and reproducible results.


Asunto(s)
Diafragma Pélvico/diagnóstico por imagen , Ultrasonografía/métodos , Incontinencia Urinaria de Esfuerzo/diagnóstico por imagen , Femenino , Humanos , Perineo , Prolapso
14.
Arch Ital Urol Androl ; 75(4): 217-25, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15005498

RESUMEN

INTRODUCTION: Adrenal masses discovered by imaging techniques for reasons unrelated to adrenal diseases are called incidentalomas with pheochromocytomas accounting for about 20%. The aim of this study was to report on our experience of 5 patients operated for incidentally discovered adrenal pheochromocytoma and update the literature concerning this subject. PATIENTS AND METHODS: From September 1976 to December 2000 we operated on 28 for adrenal incidentaloma, and pheochromocytoma was detected in 5 patients (19%). Average age was 61.4 years (range 54-65). All patients underwent adrenal hormonal as well as imaging investigation. Preoperative care for pheochromocytoma was performed in 3 patients. All patients were followed up. RESULTS: Average tumor diameter, as detected by CT, was 5.5 cm (range 3-10). Urinary 24/h excretion of VMA resulted elevated in 2 cases (40%). Two patients during adrenalectomy developed paroxysmal hypertension which was readily controlled by intravenous administration of nitroprussiate and trandate. Postoperative outcome was uneventful. Average tumor size, as detected by pathology, resulted 8.9 cm (range 3-12). Mean follow-up was 60.4 months (range 32-122) and overall survival rate was 60%. Three patients are alive and disease-free and 2 died after a follow-up of 32 and 36 months for reasons unrelated to the primary disease. CONCLUSIONS: Every incidentally discovered adrenal mass should be investigated for pheochromocytoma since accounting for about 20%. Undetected pheochromocytomas undergoing surgery without preoperative care for avoiding cardiovascular disturbances confer a high risk for morbidity and mortality, especially in pregnancy and childhood. Nonfunctional and small tumors sized 3 cm or lesser may be closely followed up by imaging and hormonal investigation. Surgery is indicated when tumors are functional or larger than 3 cm. Actually, laparoscopy is the new gold-standard in treating adrenal pheochromocytomas. Adrenal sparing surgery as well as autotransplantation of adrenal tissue are both effective and safe in treating patients with bilateral pheochromocytomas, thus improving quality of life since avoiding lifelong steroid dependency. When managed appropriately, the outlook for pheochromocytoma is excellent with a free survival rate of 92% and 80% at 5 and 10 years respectively. Unfortunately, malignant pheochromocytomas are still difficult to treat.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Adrenalectomía , Feocromocitoma , Neoplasias de las Glándulas Suprarrenales/diagnóstico , Neoplasias de las Glándulas Suprarrenales/diagnóstico por imagen , Neoplasias de las Glándulas Suprarrenales/patología , Neoplasias de las Glándulas Suprarrenales/cirugía , Glándulas Suprarrenales/patología , Anciano , Niño , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Laparoscopía , Masculino , Persona de Mediana Edad , Feocromocitoma/diagnóstico , Feocromocitoma/diagnóstico por imagen , Feocromocitoma/mortalidad , Feocromocitoma/patología , Feocromocitoma/cirugía , Cuidados Preoperatorios , Factores de Tiempo , Tomografía Computarizada por Rayos X
15.
Arch Ital Urol Androl ; 74(3): 142-5, 2002 Sep.
Artículo en Italiano | MEDLINE | ID: mdl-12416009

RESUMEN

Primary small cell carcinoma of the urinary bladder is a highly aggressive disease and accounts for less than 0.5% of all primary bladder tumors. Quite often, clinical presentation is related to local and/or systemic involvement of the disease. Histogenesis is still unknown, but investigators consider the tumor originating from a multipotent undifferentiated stem cell of the bladder urothelium. Hematuria is the first and most frequent symptom that patients complain at the clinical presentation of the disease. The primary local tumor is treated by radical surgery or radiation therapy, while systemic involvement requires polychemotherapy according to the M-VAC protocol. Prognosis is worse and related to the pathological stage of the disease and to chemotherapy reply. Herein we report on 3 cases of primary small cell carcinoma of the urinary biadder. We also review and update the literature concerning this topic.


Asunto(s)
Carcinoma de Células Pequeñas/patología , Neoplasias de la Vejiga Urinaria/patología , Anciano , Humanos , Masculino , Persona de Mediana Edad
16.
Arch Ital Urol Androl ; 74(3): 146-51, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12416010

RESUMEN

INTRODUCTION AND OBJECTIVES: Adrenal myelolipomas are rare benign non functioning tumors which are mostly detected incidentally by imaging (8-15%). The aim of this study was to find out the clinical outcome of 3 patients operated for incidentally discovered adrenal myelolipoma as well as to update the literature concerning this topic. PATIENTS AND METHODS: During a 24 year period (1976-2000) we operated on 28 of 39 (72%) patients for incidentally discovered adrenal mass and pathology assessed 3 myelolipomas (11%). All patients were males and average age was 54.3 years (range 46-66). Myelolipoma was associated with arterial hypertension in 2 patients and BPH in 1. Patients underwent unilateral adrenalectomy. Results Myelolipomas, all unilateral, were right-sided in 2 cases (67%) and left sided in 1. Average tumor diameter, as detected by CT scan, resulted 10.3 cm range (3-17). Endocrine investigation was negative. Average tumor size, as detected by pathology, resulted 9.3 cm (range 3-14) and mean weight 653 gr (range 210-980). Histopathology assessed primary adrenal myelolipoma in all cases. Mean follow-up is 110.6 months (range 102-128) and all patients are alive and disease free. CONCLUSIONS: Ultrasound (US), computed tomography (CT) and magnetic resonance imaging (MRI) are effective in diagnosing adrenal myelolipomas in about 90% of cases. Fine needle aspiration (FNA) cytology under CT or US control has an important role in investigating as well as diagnosing undefined masses suspected of adrenal or extraadrenal myelolipoma thus avoiding unnecessary surgery. The increasing number of incidentally discovered adrenal myelolipomas arise the question of appropriate treatment modalities which range from watchful waiting to surgical removal. Small asymptomatic tumors sized less than 4 cm can be monitored expectantly. Tumors when symptomatic or larger than 4 cm should be removed since the risk of spontaneous rupture with retroperitoneal hemorrhage and life threatening shock. Bilateral adrenalectomy for large and symptomatic tumors implies lifelong substitution with hydrocortisone. Actually, laparoscopic adrenalectomy is the new gold standard in treating myelolipomas since both showing more effective postoperative recovery than open surgery as well as reducing the number of patients who undergo long and close follow up.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales/cirugía , Mielolipoma/cirugía , Anciano , Humanos , Masculino , Persona de Mediana Edad
17.
Arch Ital Urol Androl ; 74(2): 77-80, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12161941

RESUMEN

INTRODUCTION: Testis cancer is the most common tumor detected in men aged from 20 to 35 years accounting for 1-2%. About 20-30% of patients presenting with clinical stage I pure seminoma of the testis, which accounts for 45-50% of all germ cell tumors, present with occult metastases in the retroperitoneal lymph nodes. Currently, treatment options for clinical stage I seminoma include adjuvant radiotherapy (RT) as well as surveillance and adjuvant single agent chemotherapy. Herein, we review our experience in the management of 42 patients with clinical stage I pure seminoma of the testis and review the literature concerning this topic. MATERIALS AND METHODS: Between January 1977 and December 2000, of 56 patients with pure seminoma of the testis 42 (75%) were assessed as clinical stage I disease. Adjuvant RT was performed in 41 patients and surveillance in 1. Radiations fields included the para-aortic and ipsilateral pelvic lymph nodes. A radiation dose of 25 Gy in 20 daily fractions was given. All patients were followed up. RESULTS: Average age was 41.2 years (range 24-67). Mean follow-up was 85.3 months (range 12-279). Histopathology assessed classic seminoma in 41 cases (98%) and spermatocytic seminoma in 1 (2%). Small vessel invasion was detected in 8 cases (19%). Overall relapse rate was 4.7%. Overall survival rate resulted 97%. CONCLUSIONS: Adjuvant radiotherapy (RT) is a safe standard of care in controlling microscopic retroperitoneal disease in patients with clinical stage I seminoma. About 3 to 5% of patients undergo relapses, mostly after the first 18 months after orchiectomy. Overall cause-specific survival rates range between 96% to 100%. An alternative optional treatment for compliant patients presenting with low risk factors for relapse is surveillance with recurrences rates ranging between 15% to 20%. Surveillance avoids unnecessary treatment in about 80% of patients, thus it could be offered as a safe alternative option to adjuvant RT since imaging detects relapses at their early stages. Adjuvant chemotherapy with 1 or 2 courses of single-agent carboplatin is being investigated as an alternative adjuvant treatment to RT or surveillance in patients with moderate to high risk factors for relapse. The treatment is well tolerated and recurrence rate is 1%.


Asunto(s)
Antineoplásicos/uso terapéutico , Carboplatino/uso terapéutico , Quimioterapia Adyuvante , Orquiectomía , Radioterapia Adyuvante , Seminoma/terapia , Neoplasias Testiculares/terapia , Adulto , Anciano , Manejo de Caso , Terapia Combinada , Estudios de Seguimiento , Humanos , Metástasis Linfática/radioterapia , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Recurrencia Local de Neoplasia/epidemiología , Estadificación de Neoplasias , Neoplasias Primarias Múltiples , Estudios Retrospectivos , Factores de Riesgo , Seminoma/tratamiento farmacológico , Seminoma/patología , Seminoma/radioterapia , Seminoma/cirugía , Tasa de Supervivencia , Neoplasias Testiculares/tratamiento farmacológico , Neoplasias Testiculares/patología , Neoplasias Testiculares/radioterapia , Neoplasias Testiculares/cirugía , Resultado del Tratamiento
18.
Arch Ital Urol Androl ; 74(2): 81-5, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12161942

RESUMEN

INTRODUCTION: About 25% of testicular seminomas present with advanced clinical stage disease. The retroperitoneal lymph nodes are more likely to be involved (20%) than distant organs (5%). Herein we review our experience in the management of 14 patients with clinical stage II pure seminoma of the testis and review the literature concerning this subject. MATERIALS AND METHODS: Between January 1977 and December 2000, of 56 patients with pure seminoma of the testis 14 (25%) were assessed as clinical stage II disease. RT was performed for clinical substage IIA-IIB and chemotherapy in for IIC disease. All patients were closely followed up. RESULTS: Average age was 39.3 years (range 23-47). Mean follow-up was 88.6 months (range 28-232). Clinical stage IIA-IIB was detected in 12 patients (86%) and IIC in 2 (14%). Relapse did not occur in any patient. At the last follow-up evaluation, all patients were alive and disease-free. CONCLUSIONS: Radiation therapy is the standard of care in managing seminoma small bulk retroperitoneal disease including substages IIA and IIB. Overall toxicity of RT is mild and treatment is well tolerated. After RT, about 20% of patients may undergo relapses. Chemotherapy is the choice treatment for advanced seminoma presenting with clinical stage IIC-III disease; recently, it has also been advocated for stage IIB when presenting with multiple small lymph nodes. Carboplatin and cisplatin are the most effective agents with complete response rates of 89-91%. Patients developing progressive disease after first-line chemotherapy undergo combined salvage chemotherapy with cisplatin, ifosfamide and vinblastine with complete response rate of 83%. Patients presenting salvage chemotherapy failure are treated with high-dose chemotherapy associated with autologous bone marrow transplantation. Residual retroperitoneal masses after chemotherapy for advanced seminoma may be assessed by imaging as poorly or well defined. Surveillance is indicated for residual masses smaller than 3 cm as well as for poorly defined masses equal or greater than 3 cm. Well defined masses equal or larger than 3 cm are treated with surgery or RT. Ongoing clinical trials for testicular germ cell metastatic disease are focused on reducing toxicity without compromising efficacy as well as exploring new salvage strategies and improving the prospect of cures and survival rates.


Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia Adyuvante , Orquiectomía , Radioterapia Adyuvante , Seminoma/terapia , Neoplasias Testiculares/terapia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Bleomicina/administración & dosificación , Carboplatino/administración & dosificación , Carboplatino/uso terapéutico , Manejo de Caso , Cisplatino/administración & dosificación , Cisplatino/uso terapéutico , Terapia Combinada , Supervivencia sin Enfermedad , Etopósido/administración & dosificación , Estudios de Seguimiento , Humanos , Ifosfamida/administración & dosificación , Metástasis Linfática , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/epidemiología , Estadificación de Neoplasias , Neoplasia Residual , Neoplasias Primarias Múltiples , Inducción de Remisión , Espacio Retroperitoneal , Estudios Retrospectivos , Factores de Riesgo , Terapia Recuperativa , Seminoma/tratamiento farmacológico , Seminoma/patología , Seminoma/radioterapia , Seminoma/cirugía , Tasa de Supervivencia , Neoplasias Testiculares/tratamiento farmacológico , Neoplasias Testiculares/patología , Neoplasias Testiculares/radioterapia , Neoplasias Testiculares/cirugía , Resultado del Tratamiento , Vinblastina/administración & dosificación
19.
Arch Ital Urol Androl ; 74(1): 44-7, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12053451

RESUMEN

OBJECTIVES: To report on a case of primary renal lymphoma (PRL) and update the literature concerning this topic. MATERIALS AND METHODS: A 48-year-old woman underwent surgery for the presumed diagnosis of renal cell carcinoma with bilateral adrenal metastases. RESULTS: The neoplasm was assessed as primary renal non-Hodgkin high grade lymphoma, diffuse large B-cell type. Then the patient underwent polychemotherapy according to the VACOP-B protocol. Unfortunately, 5 weeks later the patient was lost since missing chemotherapy and follow-up. CONCLUSIONS: PRL is a distinct pathological and clinical entity which is extremely rare and highly aggressive since disseminating rapidly from its origin. The disease usually affects adults with an average age of 60 years and slight male preponderance; however it has also been reported in childhood. Etiology factors for PRL are unknown. Several histogenetic theories of the disease have been postulated since the kidney does not normally contain lymphoid tissue. Investigators reported many classes of non-Hodgkin lymphoma which include large, small, intermediate and mixed cell types with high, intermediate or low grade histologies. The neoplastic lymphoid cells may express both B and T immunoblastic phenotypes, primary renal Hodgkin lymphoma has also been reported. The disease may present with progressive renal failure of either oliguric or non oliguric type. Imaging studies in diagnosing and staging primary renal lymphomas include ultrasound examination (US) and computed tomography (CT); there are also some reports of magnetic resonance imaging (MRI). Total body bone scan and bone marrow biopsy will complete disease clinical staging. Renal biopsy is important in assessing the diagnosis of PRL as well as of acute renal failure for bilateral lymphomatous infiltration of the kidneys. Up to now, there are no standard treatment modalities for this entity since the small number of cases reported. Multidrug chemotherapy is mandatory for high grade lymphoma and when the disease is diagnosed preoperatively. High dose chemotherapy in the future may offer a curative approach in primary bilateral renal disease and without end-stage renal disease. Survival is extremely poor since 75% of patients die less than 1 year after operation. Prognosis may be improved by early detection of disease and by performing systemic chemotherapy.


Asunto(s)
Neoplasias Renales/patología , Linfoma de Células B Grandes Difuso/patología , Linfoma no Hodgkin/patología , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biopsia con Aguja , Bleomicina/administración & dosificación , Terapia Combinada , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Etopósido/administración & dosificación , Femenino , Humanos , Inmunofenotipificación , Riñón/patología , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/cirugía , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/cirugía , Linfoma no Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/cirugía , Persona de Mediana Edad , Estadificación de Neoplasias , Nefrectomía , Prednisona/administración & dosificación , Vincristina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...